Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 7, 2012, Pages 983-990

  Canto E ^a   Reverter, F ^b   Morcillo Suarez C ^c,d   Matesanz, F ^e   Fernandez O ^f   Izquierdo, G ^g   Vandenbroeck, K ^h,i   Rodriguez Antiguedad A ^j   Urcelay, E ^k   Arroyo, R ^k   Otaegui, D ^l   Olascoaga, J ^l   Saiz, A ^m   Navarro, A ^d,n   Sanchez, A ^o   Dominguez C ^a,p   Caminero, A ^a   Horga, A ^a   Tintore M ^a   Montalban, X ^a   Comabella, Manuel ^a   more..

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUTE OF EVOLUTIONARY BIOLOGY CSIC UNIVERSITAT POMPEU FABRA   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^h UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

ⁱ BASQUE FOUNDATION FOR SCIENCE   (Spain)

^j HOSPITAL DE BASURTO   (Spain)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^l BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^o HUVH   (Spain)

^p INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

chitinase 3 like 1; multiple sclerosis; polymorphisms

Indexed keywords

BETA1A INTERFERON; CHITINASE 3 LIKE 1 PROTEIN; GENOMIC DNA; INTERFERON BETA SERINE; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CHITINASE 3 LIKE 1 GENE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENE; GENOTYPE; HETEROZYGOTE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEURORADIOLOGY; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 84863197966     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511433063     Document Type: Article

References (17)

1. Kzhyshkowska J, Gratchev A and Goerdt S. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark Insights 2007; 2: 128-146.
2. Hakala BE, White C and Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993; 268: 25803-25810. (Pubitemid 23358198)
3. Kawada M, Hachiya Y, Arihiro A and Mizoguchi E. Role of mammalian chitinases in inflammatory conditions. Keio J Med 2007; 56: 21-27. (Pubitemid 46588469)
4. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006; 53: 172-209. (Pubitemid 43772025)
5. Johansen JS, Stoltenberg M, Hansen M, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999; 38: 618-626. (Pubitemid 29507329)
6. Johansen JS, Drivsholm L, Price PA and Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 2004; 46: 333-340. (Pubitemid 39487308)
7. Johansen JS, Milman N, Hansen M, Garbarsch C, Price PA and Graudal N. Increased serum YKL-40 in patients with pulmonary sarcoidosis - a potential marker of disease activity? Respir Med 2005; 99: 396-402. (Pubitemid 40347821)
8. Mitsuhashi A, Matsui H, Usui H, et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol 2009; 20: 71-77.
9. Comabella M, Fernandez M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010; 133: 1082-1093.
10. Correale J and Fiol M. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis. Mult Scler 2010; 17: 521-531.
11. Lublin FD and Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
12. Morcillo-Suarez C, Alegre J, Sangros R, et al. SNP analysis to results (SNPator): a web-based environment oriented to statistical genomics analyses upon SNP data. Bioinformatics 2008; 24: 1643-1644. (Pubitemid 351966166)
13. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575. (Pubitemid 47330214)
14. Kruit A, Grutters JC, Ruven HJ, van Moorsel CC and van den Bosch JM. A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker. Respir Med 2007; 101: 1563-1571. (Pubitemid 46832220)
15. Zhao X, Tang R, Gao B, et al. Functional variants in the promoter region of Chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet 2007; 80: 12-18. (Pubitemid 46047646)
16. Ober C, Tan Z, Sun Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 2008; 358: 1682-1691. (Pubitemid 351549915)
17. Nielsen KR, Steffensen R, Boegsted M, et al. Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arthritis Res Ther 2011; 13: R109.